Wall Street Left These 2 AI Drug Stocks for Dead Right as Their Science Started Working

Recursion trades 49 percent below its 52-week intraday high while the biotech ETF XBI returned 76 percent over the same twelve months, yet its platform produced its first clinical efficacy signal.